hAnxA5 can mediate the occurrence of primary hepatocellular carcinoma (HCC) through the integrin and MEK-ERK pathways and has potential applications in the research and treatment of HCC [70]. This evidence concerns the gene MAP2K7 and hepatocellular carcinoma.